Back to search

Article

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

2023-08-01

Abstract excerpt

Topic: 4. Acute myeloid leukemia - Clinical Background: The menin and histone-lysine-N-methyltransferase 2A (KMT2A) protein complex is an essential epigenetic regulator of genes critical for maintenance of multiple genetic subtypes of leukemia. This complex is implicated in NPM1 mutant acute myeloid leukemia (AML) (NPM1m, 25-30% of AML) as well as AML with KMT2A gene rearrangements (KMT2Ar; 5-10% of AMLs). The pre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
98f082f0-5f8c-57f3-9713-74693dcd0b53
DOI
10.1097/01.hs9.0000968924.19161.da
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIADOI 10.1097/01.hs9.0000968924.19161.da
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.Semantic proximity
Ziftomenib: First Approval.Semantic proximity
Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.Semantic proximity
Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity
The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 StudySemantic proximity
Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.Semantic proximity
Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity
Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.Semantic proximity
Targeted therapy in NPM1-mutated AML: Knowns and unknownsSemantic proximity
Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity
Advancements in targeted therapies for acute myeloid leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.